The Role of Induction (Neoadjuvant) Chemotherapy in Stage IIIA NSCLC Rafael Rosell, MD, Albert Font, MD, Alex Pifarré, MD, Mercedes Canela, MD, PhD, Joan Maurel, MD, Antonio Arellano, MD, PhD, José Izquierdo, MD, PhD CHEST Volume 109, Issue 5, Pages 102S-106S (May 1996) DOI: 10.1378/chest.109.5_Supplement.102S Copyright © 1996 The American College of Chest Physicians Terms and Conditions
Figure 1 New approaches in the management of NSCLC. The numbers in the box after surgery are percentage survival figures at 1 to 6 years, taken from the Toronto study.13 CHEST 1996 109, 102S-106SDOI: (10.1378/chest.109.5_Supplement.102S) Copyright © 1996 The American College of Chest Physicians Terms and Conditions